Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:37 pm Sale |
2022-12-31 | 13G | MeiraGTx Holdings plc MGTX |
ORBIMED ADVISORS LLC | 0 0.000% |
-3,593,966 (Position Closed) |
Filing History |
| 2023-02-14 4:32 pm Purchase |
2022-12-31 | 13G | Kezar Life Sciences, Inc. KZR |
ORBIMED ADVISORS LLC | 349,512 5.100% |
349,512 (New Position) |
Filing History |
| 2023-02-14 4:30 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,200,200 (Position Closed) |
Filing History |
| 2023-02-14 4:25 pm Sale |
2022-12-31 | 13G | Harpoon Therapeutics, Inc. HARP |
ORBIMED ADVISORS LLC | 80,421 2.400% |
-86,369 (-51.78%) |
Filing History |
| 2023-02-14 4:20 pm Unchanged |
2022-12-31 | 13G | Gracell Biotechnologies Inc. GRCL |
ORBIMED ADVISORS LLC | 5,970,672 8.800% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:12 pm Unchanged |
2022-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 3,196,876 5.900% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:09 pm Sale |
2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO |
ORBIMED ADVISORS LLC | 0 0.000% |
-3,424 (Position Closed) |
Filing History |
| 2023-02-14 4:07 pm Purchase |
2022-12-31 | 13G | Applied Therapeutics, Inc. APLT |
ORBIMED ADVISORS LLC | 7,300,921 9.990% |
5,200,240 (+247.55%) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | ALX Oncology Holdings Inc. ALXO |
ORBIMED ADVISORS LLC | 2,266,000 5.600% |
2,266,000 (New Position) |
Filing History |
| 2023-02-14 4:01 pm Sale |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 71,889 2.900% |
-86,356 (-54.57%) |
Filing History |
| 2023-01-26 4:40 pm Sale |
2023-01-24 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 1,504,436 3.200% |
-325,000 (-17.77%) |
Filing History |
| 2023-01-05 4:40 pm Sale |
2023-01-03 | 13D | SpringWorks Therapeutics, Inc. SWTX |
ORBIMED ADVISORS LLC | 4,985,000 8.000% |
-614,842 (-10.98%) |
Filing History |
| 2023-01-03 5:23 pm Purchase |
2022-12-29 | 13D | Disc Medicine, Inc. IRON |
ORBIMED ADVISORS LLC | 2,160,941 12.800% |
2,160,941 (New Position) |
Filing History |
| 2022-12-28 5:14 pm Purchase |
2022-12-23 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,619,135 15.400% |
137,931 (+1.84%) |
Filing History |
| 2022-12-27 4:36 pm Sale |
2022-12-22 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 1,787,569 4.500% |
-425,002 (-19.21%) |
Filing History |
| 2022-12-27 4:25 pm Sale |
2022-12-22 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 4,260,691 5.600% |
-767,483 (-15.26%) |
Filing History |
| 2022-11-30 4:23 pm Sale |
2022-11-08 | 13D | ARS Pharmaceuticals, Inc. SPRY |
ORBIMED ADVISORS LLC | 7,788,510 8.300% |
-1 (-0.00%) |
Filing History |
| 2022-11-29 4:27 pm Purchase |
2022-11-25 | 13D | scPharmaceuticals Inc. SCPH |
ORBIMED ADVISORS LLC | 5,559,528 16.300% |
762,380 (+15.89%) |
Filing History |
| 2022-11-25 4:57 pm Sale |
2022-11-22 | 13D | TRICIDA INC TCDAQ |
ORBIMED ADVISORS LLC | 666,667 1.100% |
-8,951,245 (-93.07%) |
Filing History |
| 2022-11-10 4:25 pm Purchase |
2022-11-08 | 13D | Compass Therapeutics, Inc. CMPX |
ORBIMED ADVISORS LLC | 18,791,422 14.900% |
719,875 (+3.98%) |
Filing History |